Browse the corpus

Cannabis contains multiple biologically active compounds, most notably delta-9-tetrahydrocannabinol and cannabidiol, with divergent psychoactive and therapeutic effects. Despite remaining a Schedule I substance at the federal level, cannabis use has expanded rapidly due to widespread state legalization, increasing product potency, and shifting public perceptions. These trends have contributed to rising rates of cannabis use disorder, which affects a substantial proportion of regular users and is associated with neuropsychiatric, cardiovascular, cognitive, and functional harms, particularly among adolescents and individuals with psychiatric comorbidity. This course reviews cannabis pharmacology, epidemiology, regulation, and clinical implications of cannabis use disorder in modern practice. Additionally, this course outlines the neurobiological, genetic, and psychosocial factors underlying cannabis use disorder, high-risk populations, common clinical presentations of cannabis use disorder, and validated screening and diagnostic tools in diverse care settings. Participants will also gain an understanding of evidence-based management strategies, including first-line psychosocial treatments, harm reduction principles, and the distinction between medical cannabinoid use and disordered use, supporting safer, more informed, and patient-centered clinical decision-making. This activity for healthcare professionals is designed to enhance the learner's competence in identifying cannabis use disorder, performing the recommended evaluation and screening, and implementing an appropriate interprofessional approach when managing this condition to improve patient outcomes. Objectives: Identify the neurobiological mechanisms contributing to cannabis use disorder. Screen patients using validated tools to detect cannabis use disorder across clinical settings. Apply evidence-based treatment modalities to promote recovery in patients with cannabis use disorder. Coordinate interprofessional management strategies to improve care collaboration and outcomes in patients with cannabis use disorder. Access free multiple choice questions on this topic.

Cannabis contains numerous biologically active constituents, most notably delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). THC mediates most psychoactive effects via CB1 receptor agonism. CBD is nonintoxicating and may modulate THC effects through several mechanisms (eg, low-affinity cannabinoid receptor interactions and serotonergic signaling), though clinical effects depend on dose and formulation.[1] Cannabis remains Schedule I federally; state laws vary; FDA-approved cannabinoids exist for limited indications.[FDA. FDA and Cannabis: Research and Drug Approval Process. 2023] Despite these exceptions, cannabis use continues to expand rapidly amid shifting public perception and widespread state legalization. As of February 2024, the Centers for Disease Control and Prevention (CDC) reports that 47 states, the District of Columbia, and 3 territories permit some form of medical cannabis use. Among these, 38 states, the District of Columbia, and 3 territories operate comprehensive medical programs allowing cannabis products beyond low-THC or CBD-only formulations. Additionally, 24 states, 2 territories, and the District of Columbia have legalized nonmedical (adult-use) cannabis through state or territorial legislation.[CDC. State Medical Cannabis Laws. 2024] Globally, cannabis is the fourth most commonly used psychoactive substance after alcohol, caffeine, and tobacco, with an estimated 147 million users worldwide, although global prevalence estimates have continued to rise.[WHO. Alcohol, Drugs and Addictive Behaviours. 2016] Over the past 2 decades, the average THC potency of cannabis products has increased 3- to 5-fold, amplifying the risk of neuropsychiatric, cardiovascular, and cognitive complications.[2] Cannabis Use Disorder

Globally, cannabis is the fourth most commonly used psychoactive substance after alcohol, caffeine, and tobacco, with an estimated 147 million users worldwide, although global prevalence estimates have continued to rise.[WHO. Alcohol, Drugs and Addictive Behaviours. 2016] Over the past 2 decades, the average THC potency of cannabis products has increased 3- to 5-fold, amplifying the risk of neuropsychiatric, cardiovascular, and cognitive complications.[2] Cannabis Use Disorder Among regular users, estimates suggest that approximately 20% to 30% may meet criteria for CUD, with risk increasing with daily use, early initiation, and high-potency products.[3] Psychosocial interventions, including cognitive behavioral therapy (CBT), motivational enhancement therapy, and contingency management, remain first-line treatments. However, as of 2025, no pharmacologic therapy is FDA-approved for CUD. Trials of THC analogs, cannabidiol, gabapentin, N-acetylcysteine, and antidepressants have shown inconsistent or modest benefit.[4] The rising prevalence of CUD, occurring alongside expanded legalization and diminishing perceived risk, underscores the need for early screening, patient education, and coordinated interprofessional management. Historically, cannabis has been cultivated for medical, spiritual, and industrial purposes. The modern resurgence of scientific and clinical interest reflects these traditional uses but demands rigorous evidence-based evaluation to distinguish legitimate therapeutic benefit from misuse.[WHO. WHO Review of Cannabis and Cannabis-Related Substances. 2019][3]

CUD develops through the interaction of biological, genetic, and psychosocial factors that influence the initiation and persistence of use. Vulnerability is most significant during adolescence and among individuals with psychiatric comorbidities or environmental exposure to substance use. Biological Factors THC, the primary psychoactive cannabinoid, stimulates cannabinoid type-1 (CB1) receptors within corticolimbic circuits that regulate reward and executive control. Repeated exposure disrupts endocannabinoid signaling and inhibitory regulation, fostering tolerance and withdrawal. High-potency products (>15%–20% THC) and concentrated formulations such as oils and distillates increase CUD risk in a dose-response pattern and are associated with greater psychiatric morbidity.[5] Genetic Factors CUD shows substantial heritability (approximately 30%–80%). Estimates vary by study design and phenotype. Genome-wide studies identify polygenic risk involving dopaminergic, glutamatergic, and endocannabinoid pathways (eg, CNR1, FAAH, DRD2) that overlap with vulnerability to other substance use and psychiatric disorders.[6][7][8] Environmental factors, eg, stress, peer influence, and substance availability, further modulate expression of this genetic risk. Psychosocial and Environmental Factors Early exposure to parental or peer substance use, adverse childhood experiences, and socioeconomic disadvantage increases risk. National data confirm that social engagement, curiosity, and stress relief remain predominant motives among adolescents and young adults.[SAMHSA. Marijuana and CBD. 2025] Perceived safety contributes to cannabis use among some pregnant individuals seeking relief of nausea or anxiety despite potential fetal neurodevelopmental harm.[9][10] Inhalation routes (smoked or vaped) deliver THC rapidly and at higher concentrations than oral ingestion, heightening dependence potential.[11] Psychiatric Comorbidity and Special Populations

Early exposure to parental or peer substance use, adverse childhood experiences, and socioeconomic disadvantage increases risk. National data confirm that social engagement, curiosity, and stress relief remain predominant motives among adolescents and young adults.[SAMHSA. Marijuana and CBD. 2025] Perceived safety contributes to cannabis use among some pregnant individuals seeking relief of nausea or anxiety despite potential fetal neurodevelopmental harm.[9][10] Inhalation routes (smoked or vaped) deliver THC rapidly and at higher concentrations than oral ingestion, heightening dependence potential.[11] Psychiatric Comorbidity and Special Populations CUD frequently coexists with depression, anxiety, bipolar disorder, psychosis, and posttraumatic stress disorder, and these comorbidities are associated with more severe clinical courses and poorer functional outcomes.[12][13][14][15] Cannabis use is also prevalent among individuals receiving opioid agonist therapy and may reduce treatment adherence and recovery rates.[16] High-risk populations include adolescents, pregnant individuals, patients with chronic pain or opioid use disorder, people with HIV, and those with multiple sclerosis, among whom approximately 10% to 20% of users meet diagnostic criteria for CUD.

Cannabis is among the most widely used psychoactive substances worldwide. In the United States, the 2023 National Survey on Drug Use and Health (NSDUH) reported that 15.4% of individuals aged 12 years or older (43.6 million) used marijuana in the past month and 61.8 million in the past year. Approximately 6.8% (19.2 million) met criteria for past-year marijuana use disorder (cannabis use disorder), with the highest prevalence (16.6%) among adults aged 18 to 25 years. Daily and near-daily use (primary drivers of cannabis addiction) has increased since 2015, paralleling expanded legalization, commercialization, and rising product potency.[SAMHSA. Key Substance Use and Mental Health Indicators in the United States: Results from the 2023 National Survey on Drug Use and Health. 2024] Adolescents remain particularly vulnerable. The Monitoring the Future 2023 survey found that 14% to 15% of United States high-school students reported past-month use, and cannabis vaping has increased substantially since 2017. Initiation before age 15 is associated with approximately double the lifetime risk of CUD compared with later initiation.[NIH. Monitoring the Future. 2024] Among adults aged 50 and older, prevalence has more than doubled since 2015, often for perceived medical benefits, raising concerns about intoxication, falls, polypharmacy, and drug interactions.[17] Prenatal cannabis use rose from 1.3% in 2002 to about 7% in 2018. Because THC crosses the placenta and concentrates in breast milk, both the American College of Obstetricians and Gynecologists and the American Academy of Pediatrics (2023) recommend complete abstinence during pregnancy and lactation.[18][19] Unintentional pediatric ingestion has increased sharply, with thousands of reported exposures in children younger than 6 years between 2017 and 2022, underscoring the need for child-resistant packaging and safe storage.[20][21] Jurisdictions with legalization have shown higher rates of cannabis use and CUD in some studies, with disproportionate impact among young adults and individuals with comorbid mental illness.[22]

Neurobiology Chronic cannabis exposure induces adaptive changes in reward, stress, and executive circuits that sustain tolerance and compulsive use. The psychoactive compound THC binds to CB1 and cannabinoid type-2 (CB2) receptors. CB1 receptors are dense in cortical, limbic, and striatal regions, whereas CB2 receptors are predominantly expressed in immune cells; CNS expression is lower but can be upregulated in inflammation.[23][1] Receptor Signaling CB1 activation inhibits adenylyl cyclase, lowers cyclic AMP levels, and modulates calcium and potassium channels, thereby suppressing presynaptic release of gamma-aminobutyric acid (GABA) and glutamate. These actions indirectly affect dopaminergic tone in the mesocorticolimbic pathway, influencing reward, motivation, and stress.[24] Reinforcement and Withdrawal THC indirectly increases mesolimbic dopamine signaling. Repeated exposure downregulates CB1 receptors, producing tolerance.[25] Withdrawal results from reduced endocannabinoid tone and CRF-driven amygdalar hyperactivity, leading to irritability, anxiety, and insomnia. Neuroimmune and Glial Effects Microglia and astrocytes mediate endocannabinoid signaling. Persistent activation promotes cytokine release, neuroinflammation, and synaptic remodeling, impairing executive control.[26] Adolescent Vulnerability During adolescence, the endocannabinoid system guides pruning and myelination. Cannabis exposure disrupts these processes, causing lasting prefrontal–striatal changes and increasing lifetime risk for mood, cognitive, and substance-use disorders.[27][28] Potency and Route High-THC products (≥15%–20%) and concentrates cause rapid CB1 occupancy and greater corticolimbic disruption. Inhalation delivers faster, higher peaks than ingestion, heightening the potential for dependence.[29][11] Cannabinoid Hyperemesis Syndrome Cannabinoid hyperemesis syndrome results from chronic dysregulation of CB1-mediated gut–brain emetic pathways and altered TRPV1 signaling. The temporary relief achieved with hot bathing is attributed to TRPV1 activation, whereas complete and sustained resolution requires cessation of cannabis use.[30] Functional and Genetic Changes

Cannabinoid hyperemesis syndrome results from chronic dysregulation of CB1-mediated gut–brain emetic pathways and altered TRPV1 signaling. The temporary relief achieved with hot bathing is attributed to TRPV1 activation, whereas complete and sustained resolution requires cessation of cannabis use.[30] Functional and Genetic Changes Neuroimaging shows reduced connectivity between the prefrontal cortex and the anterior cingulate cortex, as well as altered striatal activity, paralleling deficits in attention and motivation. Genetic and epigenetic studies link cannabis use to psychotic and affective disorders.[31] CUD results from convergent neurobiological and genetic mechanisms. Chronic THC exposure disrupts reward and stress regulation via CB1 downregulation, neuroimmune activation, and developmental interference. The endocannabinoid system remains a key target for future therapeutic strategies.[1]

Clinical assessment of CUD begins with identification of the phase of use, including acute intoxication, chronic or heavy use, or withdrawal, accompanied by a focused mental status evaluation.[39] During intoxication, patients may exhibit euphoria or anxiety, laughter, increased appetite, inattention, restlessness, tachycardia, conjunctival injection, and dry mouth, with occasional illusions or brief hallucinations that preserve reality testing. Chronic use or withdrawal commonly presents with depressed mood, apathy, irritability, poor concentration, and social withdrawal.[40][41][42] Brief cognitive screening, eg, 3-word recall or short-story recall, may reveal deficits in attention or memory. Persistent affective symptoms during periods of abstinence suggest an underlying primary psychiatric disorder, and evaluation should always include assessment of suicide or violence risk. High-potency concentrates administered by vaping or dabbing produce faster onset and more severe effects than smoked or edible formulations. Key History Elements Clinical history components in patients with suspected CUD include characterization of use patterns and severity, encompassing frequency, potency, route of administration, escalation, failed cessation attempts, and functional consequences. Risk assessment should address coingestants, pediatric exposure, impaired driving, medical comorbidities, cardiovascular symptoms, and pregnancy or lactation status. Clinicians should perform a safety evaluation screening for suicidality, psychosis, agitation, panic, or delirium, along with consideration of legal or occupational implications related to impairment or testing. Moreover, cyclic vomiting relieved by hot bathing and recurring after use suggests cannabinoid hyperemesis syndrome, warranting exclusion of gastrointestinal or metabolic causes. Focused Physical Examination

Clinical history components in patients with suspected CUD include characterization of use patterns and severity, encompassing frequency, potency, route of administration, escalation, failed cessation attempts, and functional consequences. Risk assessment should address coingestants, pediatric exposure, impaired driving, medical comorbidities, cardiovascular symptoms, and pregnancy or lactation status. Clinicians should perform a safety evaluation screening for suicidality, psychosis, agitation, panic, or delirium, along with consideration of legal or occupational implications related to impairment or testing. Moreover, cyclic vomiting relieved by hot bathing and recurring after use suggests cannabinoid hyperemesis syndrome, warranting exclusion of gastrointestinal or metabolic causes. Focused Physical Examination Targeted physical examination emphasizes vital signs, including tachycardia, transient hypertension, hydration status, and level of consciousness. Head and neck assessment may reveal conjunctival injection or xerostomia. The neurologic and mental status examinations should evaluate orientation, attention, memory, and impulsivity. Cardiopulmonary assessment addresses chest pain or respiratory distress, recognizing that chronic vaping or smoking may precipitate pneumothorax. In pediatric patients, vigilance for central nervous system depression or respiratory failure remains essential, with careful evaluation of exposure sources. Typical Presentations Typical intoxication presents with impaired coordination, euphoria or anxiety, altered time perception, and impaired judgment, accompanied by at least 2 physical signs, eg, conjunctival injection, dry mouth, tachycardia, or increased appetite. Withdrawal following heavy use typically manifests with 3 or more symptoms within 1 week, including irritability, anxiety, insomnia, appetite loss, restlessness, or depressed mood, plus at least 1 physical symptom, eg, abdominal pain, tremor, sweating, fever, chills, or headache. Symptom onset occurs within 24 hours, peaks by day 3, and resolves over approximately 2 weeks.[40] Cannabis-Induced Psychiatric Syndromes

Typical intoxication presents with impaired coordination, euphoria or anxiety, altered time perception, and impaired judgment, accompanied by at least 2 physical signs, eg, conjunctival injection, dry mouth, tachycardia, or increased appetite. Withdrawal following heavy use typically manifests with 3 or more symptoms within 1 week, including irritability, anxiety, insomnia, appetite loss, restlessness, or depressed mood, plus at least 1 physical symptom, eg, abdominal pain, tremor, sweating, fever, chills, or headache. Symptom onset occurs within 24 hours, peaks by day 3, and resolves over approximately 2 weeks.[40] Cannabis-Induced Psychiatric Syndromes Cannabis exposure may precipitate transient substance-induced delirium, psychosis, anxiety, or sleep disturbance during intoxication or withdrawal when symptom severity exceeds expected effects. Ongoing psychotic symptoms beyond periods of use favor a primary psychiatric disorder.[43] Accurate diagnosis and management depend on determining the phase of use, assessing safety, documenting patterns, potency, and functional impact, recognizing cannabinoid hyperemesis syndrome and psychiatric manifestations, and distinguishing substance-induced symptoms from primary mental illness.

Evaluation of CUD integrates validated screening tools, structured diagnostic interviews, and clinical judgment to distinguish problematic use from therapeutic or recreational consumption. According to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR), CUD is a chronic, relapsing condition marked by impaired control and continued use despite harm. Diagnosis requires at least 2 of 11 criteria within 12 months across 4 domains—impaired control, social or occupational dysfunction, risky use, and tolerance or withdrawal.[44][45] The severity of CUD is classified as mild (2–3 criteria), moderate (4–5), or severe (≥6); sustained remission denotes the absence of CUD criteria for 12 months or more (see Table 1).[46][47][45] Table Table 1. DSM-5 Diagnostic Criteria, Severity Classification, and Remission Specifiers for Cannabis Use Disorder. Screening and Initial Assessment Screening should occur privately and nonjudgmentally, prompted by behavioral or physical indicators such as cognitive decline, conjunctival injection, cannabis odor, tachycardia, impaired coordination, or hyperphagia. Validated tools include: SIS-C: Single-item past-year use screen (sensitivity 0.88, specificity 0.83) [48] CUDIT-R: Contains 8 items on consumption and consequences (cutoff ≥9 for young adults; 10–14 for veterans) [49] CUDIT-C: A 3-item version for rapid assessment (sensitivity 0.91, specificity 0.84) ASSIST: Multisubstance tool validated for cannabis in primary care [50] Positive screens warrant detailed interviews assessing frequency, dose, route, potency, motives, and functional effects. Screening identifies risk but does not confirm diagnosis. Laboratory Testing and Interpretation Toxicology confirms exposure but not intoxication or severity. The following specimens have varying detection windows: Urine: THC-COOH is detectable for approximately 3 days after a single use and up to 30 days in chronic users. Blood/saliva: Detection in these specimens reflects recent use (<24 hours); mainly forensic or occupational use. Hair: Detection in hair samples indicates long-term exposure without temporal precision.[51]

Toxicology confirms exposure but not intoxication or severity. The following specimens have varying detection windows: Urine: THC-COOH is detectable for approximately 3 days after a single use and up to 30 days in chronic users. Blood/saliva: Detection in these specimens reflects recent use (<24 hours); mainly forensic or occupational use. Hair: Detection in hair samples indicates long-term exposure without temporal precision.[51] Results confirm exposure only; negative tests do not exclude use. Quantitative levels may approximate tolerance but are unreliable. Prototype breath tests for recent (<3 hours) use remain investigational. Routine laboratory studies are unnecessary unless psychosis, cognitive changes, or systemic illness warrant targeted evaluation (eg, metabolic, hepatic, or infectious panels).[52] Structured Diagnostic Evaluation Assessment should quantify patterns of use, craving, withdrawal symptoms, and the degree of functional impairment. Structured diagnostic interviews, such as the CIDI-SAM, align clinical findings with DSM-5-TR criteria and support consistent grading of disorder severity.[45] Notably, tolerance or withdrawal related to prescribed cannabinoid therapy does not indicate cannabis use disorder unless accompanied by impaired control, distress, or functional consequences. Psychometric and Dimensional Validation Psychometric and dimensional analyses support a single continuum of severity across DSM-5-TR criteria.[45] Highly discriminative features include craving, unsuccessful attempts to cut down, and continued use despite harm. Rasch and item-response modeling demonstrate reliability across diverse populations.[53] Tolerance and withdrawal contribute variable diagnostic weight, while cluster analyses identify subgroups characterized predominantly by craving and withdrawal or by social and occupational dysfunction, highlighting the need for individualized assessment approaches.[47] Special Populations

Psychometric and dimensional analyses support a single continuum of severity across DSM-5-TR criteria.[45] Highly discriminative features include craving, unsuccessful attempts to cut down, and continued use despite harm. Rasch and item-response modeling demonstrate reliability across diverse populations.[53] Tolerance and withdrawal contribute variable diagnostic weight, while cluster analyses identify subgroups characterized predominantly by craving and withdrawal or by social and occupational dysfunction, highlighting the need for individualized assessment approaches.[47] Special Populations Special populations require tailored evaluation strategies. In patients with psychotic or mood disorders, verification of temporal relationships between cannabis exposure and symptom onset using collateral information or toxicology improves diagnostic accuracy. Among veterans, the CUDIT-R remains a valid screening tool and should be integrated with assessment for posttraumatic stress disorder and depression.[54][55] In emergency and trauma settings, routine screening enhances detection among injured or impaired drivers.[56] Evaluation Overview A comprehensive evaluation of cannabis use disorder integrates validated screening instruments, eg, the SIS-C, CUDIT-R, or CUDIT-C, and ASSIST; structured diagnostic interviews, including the CIDI-SAM; context-specific toxicology testing; and thorough functional and contextual assessment. Knowledge of THC pharmacokinetics, interpretation of results within clinical context, and recognition of population-specific patterns, including adolescents, veterans, and individuals with psychiatric comorbidity, enhance diagnostic precision and support individualized management.

Goals and Care Settings Management of CUD relies on evidence-based psychosocial interventions, notably cognitive behavioral therapy (CBT), motivational enhancement therapy, and their combination with contingency management as a key adjunct. Supportive care during intoxication and withdrawal, structured monitoring, and concurrent management of psychiatric comorbidities are essential. Pharmacologic and neuromodulation therapies remain investigational, with no FDA-approved options. Given persistently low treatment engagement and rising prevalence, clinicians should emphasize accessible, integrated, and culturally responsive care pathways. The primary objective is to improve overall functioning and reduce cannabis-related harms. Most cases of CUD are managed outpatient; inpatient care is reserved for suicidality, psychosis, severe withdrawal, or polysubstance use.[1] Goals may include abstinence or harm reduction (fewer use-days, lower potency, safer routes).[57][58] Early sessions should emphasize engagement and motivational readiness. Acute Intoxication and Withdrawal In patients meeting the criteria of acute intoxication and withdrawal, observation and supportive care are primary, and assess for coingestants/suicide risk/psychosis: Acute intoxication: Usually self-limited; manage in a calm environment with reassurance and monitoring. Tachycardia/anxiety: supportive psychotherapy first; clonidine or β-blockers briefly, and consider contraindications Severe panic/agitation: short-course benzodiazepines may be used cautiously. Anxiety/insomnia: supportive psychotherapy; consider first-generation antihistamines in moderate to severe symptoms Persistent psychosis: antipsychotics with evaluation for primary psychiatric disorder or coingestants. Withdrawal: Onset within 24 hours, peak at 3 days, resolution by 2 weeks. Supportive care is the primary therapy.[57][40] Hydration, NSAIDs for myalgias Sleep hygiene [59] Clonidine or gabapentin for irritability or insomnia Psychoeducation (monitor mood, suicidality, psychosis) Psychosocial Interventions (First-Line) Behavioral therapy is the cornerstone of the management of CUD; combining modalities enhances the effect.[1] Interventions include: Brief interventions: 1 to 2 sessions; transient benefit CBT: coping skills, triggers, problem-solving; 6 or more sessions [1][60][61] Motivational enhancement therapy: readiness enhancement; best when combined with CBT [62]

Behavioral therapy is the cornerstone of the management of CUD; combining modalities enhances the effect.[1] Interventions include: Brief interventions: 1 to 2 sessions; transient benefit CBT: coping skills, triggers, problem-solving; 6 or more sessions [1][60][61] Motivational enhancement therapy: readiness enhancement; best when combined with CBT [62] Motivational enhancement therapy plus CBT: superior to either alone Contingency management: strongest evidence; use if limited early progress.[63] Family-based therapy (FBT/MDFT): for adolescents and young adults Emerging modalities: Acceptance and Commitment Therapy (ACT) and Dialectical Behavior Therapy (DBT)-informed approaches show early promise Digital and telehealth care: Web-based, app-based, or text-based CBT/motivational enhancement therapy/contingency management programs (eg, PNC-txt) expand access and can reduce frequency of use, particularly in stepped-care or rural/low-resource settings [64] Mutual-help groups: Marijuana Anonymous, SMART Recovery, or Narcotics Anonymous may support maintenance, though evidence is limited Treatment Planning and Monitoring Focus on reducing use-days over grams. Begin weekly, taper as stable. Use urine toxicology by agreement. Include family/partner support. If response is suboptimal, combine CBT plus motivational enhancement therapy with or without contingency management. Reassess regularly and adapt goals.[57] Pharmacologic and neuromodulation options (investigational) The following agents or modalities have no FDA-approved pharmacotherapy as evidence remains inconsistent: N-acetylcysteine: adolescent signal, not adult-replicated [65] [65]Gabapentin: helps sleep/anxiety; sedation risk Nabiximols (THC:CBD 1:1): mixed outcomes [66] CBD (400–800 mg): reduced THC metabolite ratios and increased abstinent days demonstrated by randomized control studies, but inconsistent replication [67][68] Topiramate: may reduce consumption but often limited by adverse effects [69] Varenicline, Ketamine-assisted therapy: modest reductions in use-days suggested by small studies Semaglutide: retrospective data suggest a lower incidence of CUD; prospective trials are ongoing Agents without benefit: antidepressants, mood stabilizers, cannabinoid agonists, atomoxetine, buspirone, zolpidem Neuromodulation: rTMS targeting the dorsolateral prefrontal cortex (DLPFC) shows inconsistent results and is not recommended outside research settings [70][71][72]

Semaglutide: retrospective data suggest a lower incidence of CUD; prospective trials are ongoing Agents without benefit: antidepressants, mood stabilizers, cannabinoid agonists, atomoxetine, buspirone, zolpidem Neuromodulation: rTMS targeting the dorsolateral prefrontal cortex (DLPFC) shows inconsistent results and is not recommended outside research settings [70][71][72] Comorbidity Management Comorbidity management requires concurrent treatment of coexisting psychiatric illness to optimize outcomes.[43] Anxiety disorders, depressive disorders, bipolar disorder, posttraumatic stress disorder, and psychotic disorders should receive guideline-concordant treatment alongside interventions for CUD. Cannabis cessation in individuals with psychotic disorders is associated with improved clinical outcomes and reduced relapse risk.[73][74] In patients with attention-deficit/hyperactivity disorder, behavioral therapy and digital interventions, eg, CANreduce 2.0, support meaningful reductions in cannabis use. Targeted management of sleep disturbance, chronic pain, and trauma-related symptoms further reduces relapse vulnerability. Special Populations and Health Equity Special populations require tailored, equity-focused approaches. In adolescents, care should prioritize cognitive behavioral therapy, motivational enhancement therapy, and family-based therapy, while pharmacologic options remain investigational.[75] Among veterans and individuals using cannabis for medical purposes, screening with the CUDIT-R and ongoing monitoring for escalation or emerging impairment remain essential. Women and minoritized populations benefit from culturally responsive, flexible models of care that address structural and access-related disparities. In patients with neurologic or pediatric disorders, cannabidiol use should remain limited to specific epilepsies, with specialist oversight required for other indications. Harm Reduction and Functional Outcomes

Special populations require tailored, equity-focused approaches. In adolescents, care should prioritize cognitive behavioral therapy, motivational enhancement therapy, and family-based therapy, while pharmacologic options remain investigational.[75] Among veterans and individuals using cannabis for medical purposes, screening with the CUDIT-R and ongoing monitoring for escalation or emerging impairment remain essential. Women and minoritized populations benefit from culturally responsive, flexible models of care that address structural and access-related disparities. In patients with neurologic or pediatric disorders, cannabidiol use should remain limited to specific epilepsies, with specialist oversight required for other indications. Harm Reduction and Functional Outcomes Meaningful improvement may occur without full abstinence. Reducing use by roughly 50% in frequency and 75% in total amount is linked to fewer cannabis-related problems and better functioning.[73] Harm reduction focuses on supportive counseling, safe product storage, and preference for lower-THC, non-inhaled forms. Patients should set individualized goals, recognize impairment risks, and understand that links between cannabis use and reduced opioid consumption are correlational, not causal. Medical Use of Cannabis and Cannabinoids Cannabis and cannabinoid products show therapeutic benefit in select conditions that are distinct for CUD—chronic pain, chemotherapy-induced nausea and vomiting, multiple sclerosis–related spasticity, and certain epilepsies.[76][77] Evidence for insomnia, anxiety, or appetite stimulation remains of low certainty.[78] FDA-approved agents include: Dronabinol and nabilone: approved for chemotherapy-induced nausea and vomiting and AIDS-related anorexia [79][76] [76]Cannabidiol (Epidiolex): approved for Lennox-Gastaut, Dravet, and tuberous sclerosis complex epilepsies In patients using medical cannabis and cannabinoids, the preferred administration route is noninhaled (eg, oral, sublingual, tinctures). Patients should begin with low doses (eg, 2.5 mg THC ± 2.5 mg CBD) and titrate cautiously. Concurrent use with sedatives or alcohol should be avoided. Medical-use cannabis and cannabinoids may have adverse effects, including: Common: dizziness, somnolence, dry mouth, transient cognitive slowing, anxiety

In patients using medical cannabis and cannabinoids, the preferred administration route is noninhaled (eg, oral, sublingual, tinctures). Patients should begin with low doses (eg, 2.5 mg THC ± 2.5 mg CBD) and titrate cautiously. Concurrent use with sedatives or alcohol should be avoided. Medical-use cannabis and cannabinoids may have adverse effects, including: Common: dizziness, somnolence, dry mouth, transient cognitive slowing, anxiety Serious: psychosis, cardiovascular events, and cannabinoid hyperemesis syndrome.[80] CBD may mitigate some THC-related adverse effects. Recommended clinical precautions include: Avoid during pregnancy, lactation, psychosis, or unstable cardiac disease. Monitor for sedation, cognitive impairment, and CYP450 interactions (eg, warfarin, azoles).[81][82] Screen periodically for emerging CUD. Reassess every 3 to 6 months for efficacy, adverse effects, product potency, and storage safety; reinforce no driving while impaired. Medical cannabis may provide modest, condition-specific benefit in carefully selected, refractory cases when standard therapies fail. Thorough counseling, cautious titration, and ongoing monitoring are essential to balance potential benefits against risks.

CUD must be distinguished from intoxication, withdrawal, other substance use, and primary psychiatric illnesses. Diagnosis depends on the timing of symptoms, degree of impairment, and collateral history. Substance-Related Conditions Substance-related conditions that should also be considered include: Cannabis-induced states: Intoxication, withdrawal, or cannabis-induced anxiety or psychosis appear during or soon after use and resolve with abstinence. Other substances: Stimulants: agitation, tachycardia, mydriasis, psychosis Sedatives/alcohol: withdrawal causes tremor, anxiety, insomnia, and autonomic instability Opioids: intoxication—miosis, respiratory depression; withdrawal—mydriasis, rhinorrhea, GI upset. Hallucinogens: perceptual distortion, panic, derealization. Synthetic cannabinoids: marked agitation, psychosis, seizures, or dysautonomia out of proportion to reported cannabis use.[83][84] Additionally, clinicians should perform a toxicology when symptoms exceed expected cannabis effects.[85] Primary Psychiatric Disorders Cannabis may mimic, precipitate, or coexist with other mental illnesses. Observation during abstinence is essential. Differential diagnoses include: Mood and anxiety disorders: Persistent depressive, manic, or anxious symptoms after cessation suggest a primary disorder. Neurodevelopmental disorders: ADHD and conduct disorder increase CUD risk but remain independent diagnoses. Psychotic disorders: Psychosis preceding use or lasting beyond 1 month of abstinence indicates schizophrenia; cannabis-induced psychosis resolves with abstinence and often follows high-THC exposure. Personality disorders: Antisocial or borderline traits may resemble substance-related impulsivity—compare with baseline personality.

CUD is chronic but often remits with sustained treatment and psychosocial stability. Relapse is common, particularly within the first year, often triggered by stress or comorbid psychiatric symptoms. Early onset, high-THC exposure, and untreated mental illness predict persistent or severe illness. Cognitive function improves within weeks of abstinence, with partial normalization of prefrontal activity on imaging. Integrated behavioral and psychiatric care significantly reduces relapse and improves functioning. Motivation, adherence, and supportive environments are the strongest predictors of long-term recovery and stability.[57][91]

Early initiation, frequent or high-THC use, polysubstance exposure, and psychiatric comorbidity significantly heighten neuropsychiatric, medical, and functional risks. Neuropsychiatric and Cognitive Chronic heavy use impairs attention, memory, and executive function, with alterations in prefrontal, striatal, and hippocampal networks. High-THC exposure increases psychosis risk and relapse after cannabis-induced episodes, while abstinence improves prognosis. CUD is linked to depression and anxiety; perceived symptom relief in posttraumatic stress disorder (PTSD) often diminishes with tolerance and dependence.[92] Women may experience greater vulnerability to anxiety and cognitive effects.[91][93][94][95][96] Function and Safety Heavy use correlates with academic and occupational underachievement, lower income, and impaired driving performance. Driving within several hours of use doubles crash risk, particularly with concomitant alcohol use.[97] Pulmonary and Respiratory Smoking cannabis causes chronic bronchitic symptoms and airflow limitation independent of tobacco. Vaping THC may precipitate EVALI, and synthetic cannabinoids can provoke seizures or respiratory failure. Cardiovascular Cannabis acutely elevates heart rate and myocardial oxygen demand. Meta-analyses associate use with increased myocardial infarction, stroke, and arrhythmia risk, especially in those with underlying cardiovascular disease. Gastrointestinal Cannabinoid hyperemesis syndrome presents as cyclic vomiting relieved by hot bathing; management includes fluids, antiemetics, and topical capsaicin, with cessation being curative. High-dose cannabidiol can transiently elevate liver enzymes, though typical exposure rarely causes hepatotoxicity.[98] Neurologic Acute intoxication impairs concentration and memory, while chronic exposure reduces processing speed and IQ with partial recovery after abstinence. Neuroimaging demonstrates hippocampal atrophy and cortical thinning in long-term users.[99] Reproductive and Perinatal Prenatal exposure increases the risk of low birth weight, preterm birth, and neurobehavioral abnormalities. THC and cannabidiol cross the placenta and accumulate in breast milk; abstinence during pregnancy and lactation is recommended.[100] Cancer and Other Systems

Acute intoxication impairs concentration and memory, while chronic exposure reduces processing speed and IQ with partial recovery after abstinence. Neuroimaging demonstrates hippocampal atrophy and cortical thinning in long-term users.[99] Reproductive and Perinatal Prenatal exposure increases the risk of low birth weight, preterm birth, and neurobehavioral abnormalities. THC and cannabidiol cross the placenta and accumulate in breast milk; abstinence during pregnancy and lactation is recommended.[100] Cancer and Other Systems Associations have been observed with testicular and head–neck cancers, though causality remains inconclusive. Synthetic cannabinoids can cause acute kidney injury and hematologic toxicity. Chronic use may contribute to xerostomia, periodontitis, and metabolic dysregulation. Mortality and Perioperative Considerations CUD is associated with increased emergency visits and crash-related mortality. Many deaths involve polysubstance use. Regular users may require higher anesthetic doses and enhanced perioperative monitoring.[101][102][103] Key Point High-frequency, high-potency use amplifies neuropsychiatric and systemic complications. Early detection, abstinence counseling, and comorbidity management are critical to reducing morbidity.

Public perception often deems cannabis harmless, yet evidence shows cognitive, psychiatric, and developmental harm—especially in adolescents, young adults, and during pregnancy. Clinicians should provide clear, empathetic counseling and promote harm reduction. Early, frequent, or high-potency use increases dependence, cognitive decline, and psychosis risk. Prenatal exposure impairs fetal growth and neurodevelopment; abstinence is advised. Parents should store cannabis securely to prevent pediatric ingestion, and adults should avoid driving after use. Among users, the risk of CUD is higher in adolescents and in those with frequent or high-potency use. Chronic heavy use heightens risks of psychosis, cognitive deficits, and cannabinoid hyperemesis syndrome. Psychosocial therapies—cognitive behavioral, motivational, contingency-based, and family-centered—are first-line, as no medication is FDA-approved. Education, open dialogue, and community engagement remain key to prevention and recovery.

The following factors should be kept in mind in the management of CUD: Clinical pearls Most intoxication is self-limited; use a calm setting, reassurance, and hydration Withdrawal: onset 24 hours or less, peak days 2 to 3, resolves in approximately 1 to 2 weeks No FDA-approved meds for CUD; first-line is MI/CBT/contingency/family-based care Disposition Outpatient: Uncomplicated intoxication/withdrawal; mild–moderate CUD with follow-up Refer/Admit: Suicidality, persistent psychosis, severe agitation, unstable medical status, pregnancy with heavy use, unsafe setting. Rapid follow-up should be arranged and coordinated with addiction medicine/psychiatry Common pitfalls Mislabeling primary mood/psychotic disorders without timing use vs abstinence Using urine THC to infer impairment or diagnose CUD Missing pediatric edible/vape exposures and cannabinoid hyperemesis syndrome; underestimating high-THC/synthetic risks Prevention and counseling Patients should be instructed to avoid cannabinoids in pregnancy/lactation; screen and educate routinely Harm reduction: delay initiation, avoid daily/high-THC use, no driving or hazardous work while impaired, avoid mixing with alcohol/sedatives Secure storage (locked, child-resistant); avoid unregulated/adulterated products; ensure longitudinal follow-up

Cannabis and its derivatives, including THC and CBD, produce a range of neuropsychiatric, cognitive, and physiological effects that vary with potency, route of administration, and patient vulnerability. While some cannabis-derived products receive FDA approval for limited indications, widespread recreational and medical use has increased the prevalence of CUD, intoxication, chronic toxicity, and cannabis-related complications such as cannabinoid hyperemesis syndrome and synthetic cannabinoid toxicity. Acute and chronic exposures can impair judgment, cognition, and cardiovascular function, while chronic heavy use elevates risk for mood disorders, neurocognitive deficits, and functional impairment. Special populations, including adolescents, pregnant individuals, veterans, and those with psychiatric or neurologic comorbidities, demonstrate increased susceptibility to adverse effects, highlighting the need for early identification, evidence-based intervention, and individualized care. Effective management of cannabis-related disorders requires clinicians to integrate validated screening tools, structured diagnostic assessments, and psychosocial treatment strategies while monitoring for acute toxicity, withdrawal, and comorbid psychiatric conditions. Physicians, advanced practitioners, and general practitioners are responsible for diagnosis, initiation of behavioral interventions, and coordination of pharmacologic therapies when indicated. Nurses and pharmacists play essential roles in patient education, monitoring adherence, and identifying adverse effects or drug interactions. Interprofessional communication ensures the timely sharing of clinical findings, alignment on individualized care plans, and rapid response to acute events such as intoxication, synthetic cannabinoid toxicity, or cannabinoid hyperemesis syndrome. Collaborative, team-based care enhances patient safety, supports functional recovery, and promotes consistent application of evidence-based practices across clinical settings.